本报告描述了镍催化脱羰反应的发展,用于从相应的硫酯合成氟烷基硫醚 (R F SR)。容易获得、便宜且稳定的氟代烷基羧酸 (R F CO 2 H) 作为该转化中的氟代烷基 (R F ) 源。化学计量有机金属研究表明,形成R F -S 键的还原消除是催化循环中的一个具有挑战性的步骤。这导致二苯基膦二茂铁被鉴定为该转化的最佳配体。最终,该方法应用于构建多种氟代烷基硫醚 (R F SR),其中 R = 芳基和烷基。
Hemin Catalyzed Dealkylative Intercepted [2, 3]‐Sigmatropic Rearrangement Reactions of Sulfonium Ylides with 2, 2, 2‐Trifluorodiazoethane
作者:Xiaojing Yan、Chang Li、Xiaofei Xu、Xiaoyong Zhao、Yuanjiang Pan
DOI:10.1002/adsc.201901534
日期:2020.5.12
A dealkylative intercepted [2, 3]‐sigmatropic rearrangement reaction of allylic sulfides with 2, 2, 2‐trifluorodiazoethane (CF3CHN2) is reported, the commercially available and biocompatible catalyst hemin was found to efficiently catalyze this transformation across a diverse set of allylic sulfides with in situ generated CF3CHN2, providing excellent yields (up to 99%) under mild condition without
Copper-Mediated Radical Cross-Coupling Reaction of 2,2-Dichloro-1,1,1-trifluoroethane (HCFC-123) with Phenols or Thiophenols
作者:Xiao-Jun Tang、Qing-Yun Chen
DOI:10.1021/ol302962p
日期:2012.12.21
A copper-mediated cross-coupling reaction between HCFC-123 and phenols or thiophenols has been achieved. It is found that diethyl amine, which serves as both the activator and ligand of copper, plays a key role in this reaction. Two possible radical involved processes are proposed for the reaction mechanism.
MATTER OF COMPOSITION, SYNTHESIS, FORMULATION AND APPLICATION OF FL118 PLATFORM POSITIONS 7 AND 9-DERIVED ANALOGUES FOR TREATMENT OF HUMAN DISEASE
申请人:Canget BioTekpharma
公开号:US20200231596A1
公开(公告)日:2020-07-23
Described herein, are the chemical synthesis, matter of compositions, formulation, function, methods and uses of the FL118 platform Positions 7 and/or 9-derived analogues for treating cancer or other human diseases. Compounds derived from chemical modifications of the FL118 platform are employed alone or in combination with other anti-cancer agents to preclude, eliminate or reverse cancer phenotypes. This invention intends to realize unique personalized cancer treatment (personalized precision medicine) through application of a series of structural relevant individual FL118 platform-derived analogues, which target multiple cellular human disease-relevant proteins and their signaling pathways.